

IVHEM 2022



INTERNATIONAL
VIRAL HEPATITIS
ELIMINATION
MEETING

HYBRID MEETING
2-3 DECEMBER 2022
AMSTERDAM, THE NETHERLANDS



Program Book

ve **ame**



AcademicMedicalEducation.com



Welcome Message	4
Objectives	5
General Information	6
Faculty	8
Onsite Team	13
Program	14
Acknowledgments	20

Welcome Message

Dear Colleagues,

We welcome you to the **6th International Viral Hepatitis Elimination Meeting (IVHEM)**. This annual meeting for public health officials, community, clinicians, researchers, and key partners, encourages sharing experiences to advance hepatitis B (HBV) and hepatitis C (HCV) elimination goals. IVHEM provides a forum to assess the state of HBV and HCV elimination globally and nationally, present innovative prevention, testing, and treatment strategies, and discuss common challenges. This past year has seen critical milestones and opportunities for hepatitis elimination.

The World Health Organization (WHO) released the next Global Health Sector Strategies on HIV, Viral Hepatitis and Sexually Transmitted Infections for 2022-2030 - outlining priorities and targets for the final eight years to reach the global hepatitis elimination goals. Additionally, coming out the worst of the COVID-19 pandemic, the WHO are recommitting to new health priorities. There is a unique opportunity to leverage the healthcare transformations from COVID-19 for new public health campaigns - including hepatitis elimination.

HBV and C affect more than 354 million people globally, and can lead to liver disease and mortality from liver failure and hepatocellular carcinoma. Currently, there are over 1.1 million deaths per year due to gaps in testing and treatment access, with only about 20% of persons living with HCV aware of their status and an even lower 10% of persons living with HBV. With these challenges in mind, this year's meeting will present effective public health models for expanding access to testing and linkage to care for all populations. Emerging national leaders in hepatitis elimination will share their program achievements and plans.

The meeting will also highlight new tools for tracking and evaluating essential policies for elimination programs and provide a platform for discussing the success to date and potential of public-private partnerships, cutting-edge technology, and financing models. We are at a critical juncture for hepatitis elimination, and only by coming together to share data, models of care, and innovative ideas will we reach our shared HBV and HCV elimination goals.

Best wishes,

Huma Qureshi and John Ward

Program Chairs



**John Ward
MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States



**Huma Qureshi
MD**

Pakistan Medical Research Council, Karachi, Pakistan



Meeting Objectives

This meeting aims to:

- Provide a forum for knowledge exchange and discussion of practical experiences related to the clinical management of viral hepatitis;
- Provide a toolbox for the practical application of research & development for evidence-based policymaking; and
- Facilitate cross-disciplinary discussion on barriers and challenges preventing the elimination of viral hepatitis.

Learning Objectives

After participating in this activity, participants will be able to:

- Identify innovative strategies for hepatitis B and hepatitis C testing and linkage to care and how these can be applied to their program and clinical activities;
- Recognize the needs from a public health perspective and respond to these needs by reshaping their policymaking approaches;
- Further develop new or strengthen already existing foundations for political commitment, national planning, and program improvements; and
- Translate the latest research and technologies into clinical policy and practice for delivering an adequate continuum of viral hepatitis services.

General Information

Abstracts

Accepted abstracts are published in *Reviews in Antiviral Therapy & Infectious Diseases, Volume 2022_12*.

Badge Policy

All registered delegates are provided with an identity badge. Please wear your badge at all times to ensure admission to the meeting. No spare badges can be issued.

Certificate of Attendance

The certificate of attendance will be sent by e-mail to participants that have successfully completed the program and filled in the post-meeting survey.

Code of Conduct

All individuals are required to observe our Code of Conduct. We do not tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. Please report any incidents to VE and AME via info@amededu.com or to one of our on-site personnel. Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.




View in full:

www.AcademicMedicalEducation.com/our-commitment-diversity-and-inclusion

Conference Language

The official language of the meeting is English.

Enduring Materials

 Webcasts of the presentations, along with the PDF presentations will be available on www.AcademicMedicalEducation.com shortly after the meeting, granted we have received the speakers' permission.

Feedback Form

Your feedback is very valuable to us and enables us to further improve this program. At the end of each day, a survey will be sent to you via e-mail. We would like to ask you to complete it.

Networking Opportunities

In-Person

Make use of the options to network during the coffee breaks, lunches, poster reception, and networking dinner. The networking dinner is for registered delegates only. Contact the onsite team if you would like to purchase a ticket.

Virtually

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button.

Disclaimer: This meeting aims to offer participants the opportunity to share information. Academic Medical Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Academic Medical Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.



Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages, and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

Notes

You will be able to take notes in the portal during the meeting. Any notes taken throughout the event can be exported by selecting the Export icon on the top right of your screen.

Posters

During the meeting, all accepted posters are displayed in the virtual poster gallery. The poster gallery is always open for you.

For those attending in-person, there will be a poster viewing session and reception at the end of day 1 on **Friday, 2 December 2022 at 18:30 CET.**

Social Media

We encourage you to post news and tweet about **#IVHEM #IVHEM2022** on your social media accounts during the meeting. You can either post your own tweets or retweet a message from the official [@Academic_MedEdu](https://twitter.com/Academic_MedEdu).

Time Zones

Times are in Central European Time (CET). If you need to convert the times to your timezone, this website might be of interest to you: www.WorldTimeBuddy.com.

Venue

The **International Viral Hepatitis Elimination Meeting (IVHEM) 2022** will be held at the Amsterdam Marriott Hotel in Amsterdam, the Netherlands.

Virtual Platform

OnAIR is the virtual platform that will be used for the **International Viral Hepatitis Elimination Meeting (IVHEM) 2022** for those attending virtually. This is also where the recordings will be located until approximately 3 weeks after the meeting.

Organizing Committee



Danjuma K. Adda
MPH, FIMS, Dip-IMS
World Hepatitis Alliance (WHA),
Nigeria
[View Bio >](#)



Graham Cooke
MD, PhD
Imperial College London,
United Kingdom
[View Bio >](#)



Manal El-Sayed
MD, PhD
Ain Shams University,
Egypt
[View Bio >](#)



Jordan Feld
MD, MPH
Toronto Centre for Liver Disease,
Canada
[View Bio >](#)




Jessica Howell
**MBBS, FRACP, PhD, MSc,
PGDip, PH**
University of Melbourne /
Burnet Institute, Australia
[View Bio >](#)




Olufunmilayo Lesi
MD, MBA, FMCP
World Health Organization,
Switzerland
[View Bio >](#)



Rosmawati Mohamed
MD, MRCP, MIntMed, MBBS
University Malaya Medical Centre,
Malaysia
[View Bio >](#)



Huma Qureshi
MD
Pakistan Medical Research Council,
Pakistan
[View Bio >](#)



Marcelo Silva
MD
Latin American Association for the
Study of the Liver, Austral University
Hospital, Argentina
[View Bio >](#)



John Ward, MD
Coalition for Global Hepatitis
Elimination, Task Force for Global
Health / Rollins School of Public Health,
Emory University, United States
[View Bio >](#)



Scientific Committee

Rakesh Aggarwal, MD (AIIMS), DM (PGIMER), FNASc, FAMS	Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India
Po-Lin Chan, MD	World Health Organization, Philippines
Gagandeep Singh Grover, MD	Health and Family Welfare, India
Saeed Hamid, MBBS, FRCP, FRCPI, FACP, FACG, FAASLD	Aga Khan University, Pakistan
Angelos Hatzakis, MD, PhD, MSc	Athens University Medical School, Greece
Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD	Burnet Institute, Australia
Khin Pyone Kyi, MBBS, DBact, MMedSc, PhD, FRCP	Myanmar Liver Foundation, Myanmar
Jeffrey Lazarus, PhD, MIH, MA	Barcelona Institute for Global Health (ISGlobal), Spain
Maud Lemoine, MD, PhD	Imperial College London, United Kingdom
Liudmyla Maistat	Medicines Patent Pool, Switzerland
Hailemichael Desalegn Mekonnen, MD, PhD	St. Paul's Hospital Millennium Medical College, Ethiopia
Yvonne Nartey, MBChB, MSc, MPhil	Cape Coast Teaching Hospital, Ghana
Michael Ninburg	Hepatitis Education Project (HEP), United States
Ponsiano Ocama, MD, PhD	Makerere University, Uganda
Jean-Michel Pawlotsky, MD, PhD	Hôpital Henri Mondor, France
Homie Razavi, PhD, MBA	Center for Disease Analysis (CDA), United States
Shiv. K. Sarin, MD, DM, DSc. (Hony.), FNA, FNAS	Institute of Liver and Biliary Sciences (ILBS), India
Janvier Serumondo, MD	Rwanda Biomedical Centre, Rwanda
Mark Sonderup, B Pharm, MBChB, FCP(SA), MMed	University of Cape Town, South Africa
Sonjelle Shilton, MPH	Foundation for Innovative New Diagnostics (FIND), Switzerland
Nasamon Wanlapakorn, MD, PhD	Chulalongkorn University, Thailand

Speakers & Co-Chairs

**John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

[View Bio >](#)

**Graham Cooke
MD, PhD**

Imperial College London, United Kingdom

[View Bio >](#)

**Olufunmilayo Lesi
MD, MBA, FMCP**


World Health Organization, Switzerland

[View Bio >](#)

**Cielo Yaneth Ríos Hincapié
MD**

Ministry of Health and Social Protection, Colombia

[View Bio >](#)

**Ganiyu Jamiyu
MBBS, MPH-Epid., FMCPH,
WACP**

Viral Hepatitis Control Desk, Federal Ministry of Health, Nigeria

[View Bio >](#)

**Diana Alcantara-Payawal
MD, DTMH, FPCP, FPSG, FPSDE,
LIM-SEA(HMS)**

Fatima University Medical Center, Philippines

[View Bio >](#)

**Mamun Al Mahtab Shwapnil
MBBS, MSc, MD, FACG, FICP, FRCP**

Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh

[View Bio >](#)

**Manal El-Sayed
MD, PhD**

Ain Shams University, Egypt

[View Bio >](#)

**Danjuma K. Adda
MPH, FIMS, Dip-IMS**

World Hepatitis Alliance (WHA), Nigeria

[View Bio >](#)

**Osama M. Abdelkhalik**

Permanent Representative UN Mission of Egypt, United States

[View Bio >](#)

**Nida Ali
MBBS**

Coalition for Global Hepatitis Elimination, Task Force for Global Health, United States

[View Bio >](#)

**Abdulaziz Mohammed
MD, MPH**

Disease Control and Prevention, Africa CDC, Ethiopia

[View Bio >](#)



**Lee Abdelfadil
MBBS, MPH**

The Global Fund to Fight AIDS,
Tuberculosis and Malaria,
Switzerland

[View Bio >](#)



**Finn Jarle Rode
MBA**

The Hepatitis Fund,
Switzerland

[View Bio >](#)



Humberto Silva

Rotarian Action Group for Hepatitis
Eradication, Rotary Club,
Brazil

[View Bio >](#)



**Homie Razavi
PhD**

Center for Disease Analysis (CDA),
United States


[View Bio >](#)



Christian Stoeckigt

Head of Scientific Affairs &
Medical Education, Hologic
International, Spain

[View Bio >](#)



**Huma Qureshi
MD**

Pakistan Medical Research Council,
Pakistan

[View Bio >](#)



**Megan Crumpler
PhD**

Orange County Public
Health Laboratory,
United States

[View Bio >](#)



**Karen Harrington
PhD**

Head of Scientific Affairs,
Hologic USA,
United States

[View Bio >](#)



Nyawira Njeru

Director Market Access & Strategic
Partnerships, Middle East & Africa,
Hologic International, Kenya

[View Bio >](#)



**Geoffrey Dusheiko
MBBS, FCP(SA) FRCS**

Kings College Hospital,
United Kingdom

[View Bio >](#)



**Lindsey Hiebert
MPH, BS**

Coalition for Global Hepatitis
Elimination, Task Force for Global
Health, United States

[View Bio >](#)



**Manal Ghazzawi
BPharm(Hons), PharmD,
FPCP, MPH**

KnowHep Foundation Sierra Leone,
Sierra Leone

[View Bio >](#)

Speakers & Co-Chairs



Sione Crawford

Harm Reduction Victoria,
Australia

[View Bio >](#)



Sunil Solomon
MBBS, PhD, MPH

Johns Hopkins University,
United States

[View Bio >](#)



Jeffrey Lazarus
PhD, MIH, MA

Barcelona Institute for Global Health
(ISGlobal), Spain


[View Bio >](#)



Jessica Howell
**MBBS, FRACP, PhD, MSc,
PGDip, PH**

University of Melbourne /
Burnet Institute, Australia

[View Bio >](#)



Marcelo Silva
MD

Latin American Association for the
Study of the Liver, Austral University
Hospital, Argentina

[View Bio >](#)



Mark Anderson
PhD

Abbott Laboratories,
United States

[View Bio >](#)



Tommy Good
MIB, BA

Roche Molecular Systems, Inc.,
United States

[View Bio >](#)



Benjamin LaBrot,
MD

Roche Molecular Systems, Inc.,
United States

[View Bio >](#)



Christophe Martinaud
MD, PhD

Medical Director - Medical &
Scientific Affairs Europe, Middle
East & Africa, Cepheid, France

[View Bio >](#)



Your Onsite Team



Jesper Niesen
Project Manager
Jesper.Niesen@amededu.com



Michelle Wu
Junior Project Coordinator
Michelle.Wu@amededu.com



Zita Hisschemöller
Senior AV Coordinator



Michiel de Groot
AV Coordinator



Tika Tanujaya
Junior Project Coordinator



Brenda Evan
Project Manager



Brodie Bavidge
Junior Communications
Coordinator



Helen van Run
Medical Copywriter



Danielle Silva
Communications Coordinator

Day 1 | Friday, 2 December

Central European Time (CET)

1:00 PM **Welcome, Introduction, and Goals**

Huma Qureshi, MD

Pakistan Medical Research Council, Pakistan

John Ward, MD

Coalition for Global Hepatitis Elimination, Task Force for Global Health /
Rollins School of Public Health, Emory University, United States

Session 1: Hepatitis Elimination - Where Do We Stand?

Co-chairs: John Ward & Graham Cooke

1:10 PM **Progress Towards Hepatitis Elimination: WHO Perspective**

Olufunmilayo Lesi, MD, MBA, FMCP

World Health Organization, Switzerland

1:20 PM **The Lancet Gastroenterology & Hepatology Commission**

Graham Cooke, MD, PhD

Imperial College London, United Kingdom

1:30 PM **The Global Review: Update on 25 National Profiles**

John Ward, MD

Coalition for Global Hepatitis Elimination, Task Force for Global Health /
Rollins School of Public Health, Emory University, United States

1:40 PM **The Colombian National Program on Hepatitis Elimination**

Cielo Yaneth Ríos Hincapié, MD

Ministry of Health and Social Protection, Colombia

1:50 PM **The Nigerian National Program on Hepatitis Elimination**

Ganiyu Jamiyu, MBBS, MPH-Epid., FMCPH, WACP

Viral Hepatitis Control Desk, Federal Ministry of Health, Nigeria

2:00 PM **The Philippine National Program on Hepatitis Elimination**

Diana Alcantara-Payawal, MD, DTMH, FPCP, FPSG, FPSDE, LIM-SEA(HMS)

Fatima University Medical Center, Philippines

2:10 PM **The Bangladeshi National Program on Hepatitis Elimination**

Mamun Al Mahtab Shwapnil, MBBS, MSc, MD, FAGC, FICP, FRCP

Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical
University Dhaka, Bangladesh

2:20 PM **Discussion / Q&A**

2:45 PM **Coffee Break & Poster Viewing**

Session 2: Capacity-Building Session

Co-chairs: Manal El-Sayed & Danjuma K. Adda

3:30 PM **The UN Group of Friends to Eliminate Hepatitis**

Osama M. Abdelkhalek

Permanent Representative UN Mission of Egypt, United States

Nida Ali, MBBS

Coalition for Global Hepatitis Elimination, Task Force for Global Health,
United States



- 3:45 PM **New Global Initiatives**
Abdulaziz Mohammed, MD, MPH
Disease Control and Prevention, Africa CDC, Ethiopia
- 4:00 PM **Global Fund**
Lee Abdelfadil, MBBS, MPH
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
- 4:15 PM **The Hepatitis Fund**
Finn Jarle Rode, MBA
The Hepatitis Fund, Switzerland
- 4:30 PM **Hepatitis Zero Program in Brazil and Africa**
Humberto Silva
Rotarian Action Group for Hepatitis Eradication, Rotary Club, Brazil
- 4:45 PM **CDA Foundation - Using the Netflix Model to Eliminate HCV**
Homie Razavi, PhD
Center for Disease Analysis (CDA), United States
-
- 5:00 PM **Panel Discussion**
-
- Industry Symposium - Hologic**
Co-chair: Christian Stoeckigt
-
- 5:30 PM **Opening Words**
Christian Stoeckigt
Head of Scientific Affairs & Medical Education, Hologic International, Spain
- 5:35 PM **Progress in the Hepatitis Situation in the Eastern Mediterranean Region and in Pakistan**
Huma Qureshi, MD
Pakistan Medical Research Council, Pakistan
- 5:55 PM **Implementation of HCV Testing in Correctional Settings in California, United States**
Megan Crumpler, PhD
Orange County Public Health Laboratory, United States
- 6:15 PM **Discussion / Q&A**
Karen Harrington, PhD
Head of Scientific Affairs, Hologic USA, United States
Nyawira Njeru
Director Market Access & Strategic Partnerships, Middle East & Africa, Hologic International, Kenya
- 6:25 PM **Closing Remarks**
Christian Stoeckigt
Head of Scientific Affairs & Medical Education, Hologic International, Spain
-
- 6:30 PM **Poster Viewing & Welcome Reception**
-
- 7:30 PM **Networking Dinner**

Day 2 | Saturday, 3 December

Central European Time (CET)

Session 3: Hepatitis C Elimination - How Do We Get to the 2030 Targets?

Co-chairs: Lindsey Hiebert & Geoffrey Dusheiko

- 8:30 AM **Diagnosis: Impact of Stigma on Diagnosis of Hepatitis C**
Sione Crawford
Harm Reduction Victoria, Australia
- 8:45 AM **Treatment: Do We Need New DAAs, New (long-acting) Formulations, and Simplification?**
Sunil Solomon, MBBS, PhD, MPH
Johns Hopkins University, United States
- 9:00 AM **#1 A cluster randomized controlled study of the secondary distribution of HCV self-tests in households in the general population to support micro-elimination in Karachi, Pakistan**
Aliya Hasnain, MBBS
Aga Khan University Hospital, Pakistan
- 9:10 AM **#2 Progress towards WHO HCV elimination incidence targets among people with HIV: findings from the International Collaboration on Hepatitis C Elimination in HIV Cohorts**
Daniëla van Santen, PhD
Burnet Institute, Australia
- 9:20 AM **#3 Hepatitis C seroconversion among individuals with repeated testing in the country of Georgia, 2017-2021**
Davit Baliashvili, PhD
The Task Force For Global Health, Georgia
- 9:30 AM **#4 Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies**
Robert Flisiak, MD, PhD
Medical University of Bialystok, Poland
- 9:40 AM **#5 Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia**
Muhammad Radzi Bin Abu Hassan, MB.BCh, MRCP, M. MED, FRCP, FAMB
Ministry of Health Malaysia / Clinical Research Centre, Hospital Sultanah Bahiyah, Malaysia
- 9:50 AM **Discussion / Q&A**

10:05 AM **Coffee Break**

Session 4: Hepatitis B Cure - Overcoming the Challenges

Co-chairs: Jessica Howell & Jeffrey Lazarus

- 10:35 AM **Treatment Challenges of HBV HBeAg Negative**
Marcelo Silva, MD
Latin American Association for the Study of the Liver, Austral University Hospital, Argentina



10:50 AM	Patient Perspective on HBV Treatment & Cure Danjuma K. Adda, MPH, FIMS, Dip-IMS World Hepatitis Alliance (WHA), Nigeria
11:05 AM	#6 Results of a novel Hepatitis Delta Virus reflex diagnosis patient pathway in Valencia, Spain Neus Gomez-Muñoz Hospital General Universitario de Valencia, Spain
11:15 AM	#7 Documenting Hepatitis B Discrimination Globally and Its Impact Catherine Freeland, MPH Hepatitis B Foundation, United States
11:25 AM	Discussion / Q&A
Panel Discussion: What Do We Need to Screen and Monitor for Responses to Functional Cure for HBV	
11:40 AM	Status of the HBV Functional Cure and the Role of Testing Geoffrey Dusheiko, MBBS, FCP(SA) FRCS Kings College Hospital, United Kingdom
Industry - Perspective on Overcoming the Roadblocks	
12:00 AM	Representative from Abbott Laboratories Mark Anderson, PhD Abbott Laboratories, United States
12:10 AM	Representative from Roche Molecular Diagnostics Tommy Good, MIB, BA Roche Molecular Systems, Inc., United States Benjamin LaBrot, MD Roche Molecular Systems, Inc., United States
12:20 AM	Representative from Cepheid Christophe Martinaud, MD, PhD Medical Director - Medical & Scientific Affairs Europe, Middle East & Africa, Cepheid, France
12:30 AM	Panel Discussion
1:00 PM	Lunch

Session 5: Abstract-Driven Presentations

Co-chairs: Manal Ghazzawi & John Ward

- 2:00 PM **#8 Accelerating triple elimination of mother-to-child transmission of hepatitis B, HIV, and syphilis: Preliminary results from a demonstration project in Nghe An, Vietnam**
Bao Vu, MD, MA
PATH, Vietnam
- 2:10 PM **#9 Status of Key Interventions and Essential Policies for HBV and HCV elimination in sub-Saharan Africa: A Summary of National Hepatitis Elimination Profiles from Six High-Burden Countries**
Lindsey Hiebert, MPH, BS
Coalition For Global Hepatitis Elimination, Task Force For Global Health, United States
- 2:20 PM **#10 Changes in hepatitis B and hepatitis C mortality rates in Central Asia from 2015 to 2019 and reduction in mortality needed to reach 2030 WHO viral hepatitis mortality elimination targets**
Quincy Sanderlin, MS, MPH
Centers For Disease Control And Prevention, United States
- 2:30 PM **#11 Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for marginalised populations at a mobile testing unit in Madrid, Spain**
Jeffrey Lazarus, PhD, MIH, MA
Barcelona Institute for Global Health (ISGlobal), Spain
- 2:40 PM **#12 Changes in the prevalence of hepatitis B and C viral infections among adults in Sindh province, Pakistan: findings from two sero-surveys in 2007 and 2019**
Tesfa Sewunet Alamneh
Population Health Sciences, Bristol Medical School, University of Bristol, United Kingdom
-
- 2:50 PM **Discussion / Q&A**
-
- 3:00 PM **Closing Lecture: Simplification and Linkage to Care For Adolescence and Children**
Manal El-Sayed, MD, PhD
Ain Shams University, Egypt
-
- 3:20 PM Closing Remarks
-
- 3:30 PM **End of Workshop**



PLATINUM LEVEL



GILEAD

Creating Possible

Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

GOLD LEVEL

HOLOGIC®

ENDORSERS



ve **ame**



AcademicMedicalEducation.com